Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Top cancer scientists, former NIH leaders, and patient advocates warned that the Trump administration's cuts to science ...

Immunic's MS drug shows 20% risk reduction vs placebo; Entrada cuts jobs; Henlius-Sandoz deal; Cellectar explores options; ...

Novartis to acquire Regulus Therapeutics for $7/share with potential $7 CVR tied to farabursen approval. Deal values Regulus ...

GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential ...

Noma Therapy, a virtual ketamine-assisted therapy provider, has launched with $4.25 million in funding, Endpoints News ...

BridgeBio's Attruby exceeds Q1 forecasts with $36.7M in sales, 2,072 prescriptions. CEO Neil Kumar credits clinical data; ...

Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the ...

Abeona Therapeutics received FDA approval for its cell therapy to treat “butterfly skin,” a rare genetic disease that causes ...

In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight ...